Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$87.73 USD

87.73
4,499,207

-1.77 (-1.98%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $87.73 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (155 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Edwards Lifesciences (EW) Beats on Q3 Earnings, Margins Up

Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q3.

Edwards Lifesciences (EW) Q3 Earnings and Revenues Surpass Estimates

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 13.33% and 5.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Tracey Ryniec headshot

5 Spectacular Earnings Charts

These popular stocks have some of the best earnings charts of the week.

The Zacks Analyst Blog Highlights: Edwards Lifesciences, QIAGEN, IDEXX, LHC and ResMed

The Zacks Analyst Blog Highlights: Edwards Lifesciences, QIAGEN, IDEXX, LHC and ResMed

3 MedTech Growth Stocks to Scoop Up Ahead of Q3 Earnings

Here are three growth stocks from the MedTech space that investors can pick ahead of the quarterly releases.

Earnings Preview: Edwards Lifesciences (EW) Q3 Earnings Expected to Decline

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Edwards Lifesciences' (EW) Q3 Earnings?

Robust customer adoption of the TruWave disposable pressure monitoring devices and the INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q3 revenues.

Edwards Lifesciences (EW) Up 1.8% Since Last Earnings Report: Can It Continue?

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TMO vs. EW: Which Stock Is the Better Value Option?

TMO vs. EW: Which Stock Is the Better Value Option?

Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View

Despite coronavirus-hit sales, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q2. Regulatory approvals look encouraging.

Kevin Cook headshot

Bear of the Day: Penumbra (PEN)

Growth stalls for an innovator in blood clot removal and the deadly shadow of stroke with catheter-based aspiration technologies

Edwards Lifesciences (EW) Q2 Earnings and Revenues Beat Estimates

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 126.67% and 18.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Edwards Lifesciences (EW)

Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Analysts Estimate Edwards Lifesciences (EW) to Report a Decline in Earnings: What to Look Out for

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Edwards Lifesciences (EW) in Q2 Earnings?

Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.

Urmimala Biswas headshot

Medical Instruments Outlook Dull Amid Coronavirus Crisis

Many sub domains within the medical instrument space are bearing the brunt of the coronavirus-led prolonged stay-at-home orders.

Here's Why You Should Hold on to Edwards Lifesciences for Now

Investors continue to be upbeat about Edwards Lifesciences (EW) owing to its strong segmental growth and robust product demand.

Sriparna Ghosal headshot

3 Cheap MedTech Stocks Set to Gain Once Coronavirus Crisis Ebbs

Once the pandemic-led crisis eases, these MedTech stocks will likely flourish on the back of number of positive developments.

Edwards Lifesciences' SAPIEN 3 THV Cleared for Use in China

Edwards Lifesciences' (EW) SAPIEN 3 THV to be used an alternative to open-heart surgery for high and extreme-risk AS patients post approval in China.

Here's Why You Should Hold on to Edwards Lifesciences for Now

Investors continue to be optimistic about Edwards Lifesciences (EW) on robust demand for products and a promising surgical structural heart business.

Edwards Lifesciences (EW) Down 1% Since Last Earnings Report: Can It Rebound?

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences

The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences

Sheraz Mian headshot

Top Stock Research Reports for Cisco, Abbott, NextEra & Others

Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Abbott Laboratories (ABT) and NextEra Energy (NEE).

The Zacks Analyst Blog Highlights: Intel and Edwards Lifesciences

The Zacks Analyst Blog Highlights: Intel and Edwards Lifesciences

Edwards Lifesciences (EW) Beats on Q1 Earnings, Cuts '20 View

Amid the coronavirus impact on sales, Edwards Lifesciences (EW) witnesses growth in TAVR procedures led by strong therapy adoption across all geographies, particularly in the United States.